BR112023026076A2 - Terapia combinada de radioimunoconjugados e inibidores de checkpoint - Google Patents
Terapia combinada de radioimunoconjugados e inibidores de checkpointInfo
- Publication number
- BR112023026076A2 BR112023026076A2 BR112023026076A BR112023026076A BR112023026076A2 BR 112023026076 A2 BR112023026076 A2 BR 112023026076A2 BR 112023026076 A BR112023026076 A BR 112023026076A BR 112023026076 A BR112023026076 A BR 112023026076A BR 112023026076 A2 BR112023026076 A2 BR 112023026076A2
- Authority
- BR
- Brazil
- Prior art keywords
- radioimmunoconjugates
- checkpoint inhibitors
- combined therapy
- combined
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163209736P | 2021-06-11 | 2021-06-11 | |
| PCT/US2022/033058 WO2022261467A1 (en) | 2021-06-11 | 2022-06-10 | Radioimmunoconjugates and checkpoint inhibitor combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023026076A2 true BR112023026076A2 (pt) | 2024-03-05 |
Family
ID=84426354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023026076A BR112023026076A2 (pt) | 2021-06-11 | 2022-06-10 | Terapia combinada de radioimunoconjugados e inibidores de checkpoint |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240285818A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4351662A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024521418A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240021227A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117794585A (cg-RX-API-DMAC7.html) |
| AR (1) | AR126128A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022291150A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023026076A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3222948A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309243A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014778A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202317204A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022261467A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3265502A1 (en) * | 2022-08-22 | 2024-02-29 | Abdera Therapeutics Inc. | DOTA ANTIBODY CONJUGATES VHH |
| CN120897762A (zh) * | 2023-04-12 | 2025-11-04 | 康奈尔大学 | 用于治疗癌症的放射治疗缀合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7922998B2 (en) * | 2003-01-13 | 2011-04-12 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US7226577B2 (en) * | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
| KR20210099073A (ko) * | 2018-12-03 | 2021-08-11 | 퓨전 파마슈티칼즈 인크. | 방사성면역접합체와 체크포인트 억제제의 조합 요법 |
-
2022
- 2022-06-10 JP JP2023575836A patent/JP2024521418A/ja active Pending
- 2022-06-10 US US18/568,234 patent/US20240285818A1/en active Pending
- 2022-06-10 AU AU2022291150A patent/AU2022291150A1/en not_active Abandoned
- 2022-06-10 WO PCT/US2022/033058 patent/WO2022261467A1/en not_active Ceased
- 2022-06-10 CN CN202280054208.4A patent/CN117794585A/zh active Pending
- 2022-06-10 IL IL309243A patent/IL309243A/en unknown
- 2022-06-10 TW TW111121757A patent/TW202317204A/zh unknown
- 2022-06-10 MX MX2023014778A patent/MX2023014778A/es unknown
- 2022-06-10 EP EP22821133.0A patent/EP4351662A4/en active Pending
- 2022-06-10 KR KR1020247000772A patent/KR20240021227A/ko active Pending
- 2022-06-10 AR ARP220101547A patent/AR126128A1/es unknown
- 2022-06-10 BR BR112023026076A patent/BR112023026076A2/pt unknown
- 2022-06-10 CA CA3222948A patent/CA3222948A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202317204A (zh) | 2023-05-01 |
| EP4351662A4 (en) | 2026-07-01 |
| CN117794585A (zh) | 2024-03-29 |
| MX2023014778A (es) | 2024-01-15 |
| KR20240021227A (ko) | 2024-02-16 |
| CA3222948A1 (en) | 2022-12-15 |
| JP2024521418A (ja) | 2024-05-31 |
| US20240285818A1 (en) | 2024-08-29 |
| WO2022261467A1 (en) | 2022-12-15 |
| WO2022261467A9 (en) | 2023-05-04 |
| IL309243A (en) | 2024-02-01 |
| AU2022291150A1 (en) | 2023-12-21 |
| AR126128A1 (es) | 2023-09-13 |
| EP4351662A1 (en) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001433A1 (es) | Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control | |
| PT3883579T (pt) | Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| MX2023009521A (es) | Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d. | |
| MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| MX2021013317A (es) | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. | |
| MX384438B (es) | Compuestos farmacéuticos. | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| MX387283B (es) | Tratamiento del cancer con tg02. | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| BR112022008191A2 (pt) | Terapia com antagonista de lag-3 para melanoma | |
| PE20221410A1 (es) | Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80 | |
| BR112019019261A2 (pt) | Terapias de combinação para o tratamento de câncer de mama | |
| WO2022261467A9 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| JOP20250311A1 (ar) | مثبطات tyk2 وتركيبات وطرق لها | |
| MX390751B (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
| MX2020011912A (es) | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). | |
| MX2020007375A (es) | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. | |
| MX2024009317A (es) | Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidores punto de control. | |
| MX2022003628A (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. | |
| MX2023005072A (es) | Bloqueo de cd47 y terapias combinadas de los mismos para reducir la inflamacion vascular. | |
| BR112022009522A2 (pt) | Métodos de administração de voxelotor | |
| PH12022551172A1 (en) | Anti-pcsk9 antibody and use thereof |